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078 The Journal of Thoracic and Cardbjectives: The association between gastroesophageal reflux disease and idiopathic
ulmonary fibrosis has not been fully characterized. The aims of this study were to
etermine in patients with idiopathic pulmonary fibrosis (1) the prevalence of reflux
ymptoms, (2) the esophageal manometric profile, and (3) the prevalence of prox-
mal and distal esophageal reflux.
ethods: Between May 1999 and March 2006, 30 patients with idiopathic pulmo-
ary fibrosis were referred to the Swallowing Center at the University of California
an Francisco. Each patient underwent a structured symptom assessment, esopha-
eal manometry, and 24-hour dual sensor ambulatory pH monitoring.
esults: Twenty (67%) patients had abnormal esophageal reflux. Typical reflux
ymptoms, although more common in those with reflux, were not reliable as a
creening test (sensitivity 65%, specificity 71%). Sixty-five percent of patients with
bnormal reflux had a hypotensive lower esophageal sphincter. Abnormal esopha-
eal peristalsis was more common among those with reflux (50% vs 10%; P .03).
n 9 (30%) patients, acid refluxed into the proximal esophagus for over 1% of the
tudy time.
onclusions: A majority of patients with idiopathic pulmonary fibrosis have patho-
ogic reflux. Symptoms do not distinguish between those with and without reflux. In
hese patients, reflux is associated with a hypotensive lower esophageal sphincter
nd abnormal esophageal peristalsis, and often extends into the proximal esophagus.
diopathic pulmonary fibrosis (IPF) is a lethal form of interstitial lung disease
that affects 30,000 to 50,000 people in the United States. The pathophysiology
appears to involve aberrant fibroblast proliferation owing to recurrent epithelial
njury.1 The etiology is unknown. Currently, there is no effective medical therapy
or IPF, and median survival is only 3 years.
Several lines of evidence suggest an association between gastroesophageal reflux
isease (GERD) and lung fibrosis. Thirty years ago, Mays, Dubois, and Hamilton2
ound that 48 patients with lung fibrosis of unknown etiology had twice the
revalence of hiatal hernia and GERD as compared with patients with lung fibrosis
f known etiology. Patients with erosive esophagitis had a 1.36 odds ratio of
ulmonary fibrosis in a case control study of more than 200,000 US veterans.3 More
ecently, studies of patients undergoing lung transplantation have found that reflux
s common among patients with end-stage lung disease.4,5 Furthermore, distal
sophageal reflux and markers of microaspiration have been associated with the
arly onset of chronic allograft failure after transplantation, suggesting that GERD-
elated microaspiration causes direct lung injury.5,6
In the absence of an identifiable etiology, speculation has arisen that reflux may
lay a role in the pathogenesis or progression of IPF.7 Reflux is of particular interest
ecause it represents a treatable process. Recently, a case series demonstrated that
iovascular Surgery ● April 2007
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TXatients with end-stage IPF undergoing antireflux surgery
ad reduced supplemental oxygen dependence, demonstrat-
ng the safety and potential efficacy of antireflux surgery in
hese patients.8
At this time, little is known about the prevalence or
tiology of reflux in patients with IPF, and there is no
ccepted standard for screening. This retrospective study of
atients with IPF referred for lung transplantation was done
o determine (1) the prevalence of distal and proximal reflux,
2) the esophageal manometric profile, and (3) whether or not
eflux symptoms could be used to screen for reflux.
atients and Methods
ne hundred twenty patients referred for lung transplantation
nderwent esophageal testing in the University of California San
rancisco (UCSF) Swallowing Center between 1999 and March
006. Of these, 36 had a diagnosis of IPF. Six subjects were
tudied after lung transplantation, leaving a total of 30 patients
ho completed evaluation before transplantation. This study fo-
uses on this cohort of 30 pretransplant patients with IPF. Sixteen
f these patients were included in an earlier report.9 A report
escribing the esophageal testing of 109 patients with all causes of
ung disease referred for transplantation has been published else-
here.10 Referral for esophageal testing was routine for all pre-
ransplant patients since July 2003. Twenty-six subjects were
valuated after that time.
The pathologic diagnosis of usual interstitial pneumonia was
stablished by surgical lung biopsy or by pathologic review of the
xplanted lung in 25 subjects. The remaining 5 subjects were given
diagnosis of IPF on the basis of the American Thoracic Society/
uropean Respiratory Society (ATS/ERS) consensus statement crite-
ia.11 Patients with nonspecific interstitial pneumonia were excluded.
Clinic charts and electronic medical records were reviewed for
ll patients. The best estimate of steroid use and time interval
etween diagnosis of IPF and date of esophageal studies was
xtracted from these records. These results were not prospectively
onfirmed during evaluation in the Swallowing Center. Endo-
copic examination of the upper esophagus was performed only
hen clinically indicated.
ymptomatic Evaluation
ach subject underwent a standardized interview with the Swal-
Abbreviations and Acronyms
ATS/ERS American Thoracic Society/European
Respiratory Society
DLCO  diffusion of carbon monoxide in the lung
FEV1  forced expiratory volume in 1 second
GERD  gastroesophageal reflux disease
IPF  idiopathic pulmonary fibrosis
LES  lower esophageal sphincter
UCSF  University of California San Francisco
UES  upper esophageal sphincterowing Center physician or technician. Patients estimated the se- t
The Journal of Thoracicerity of their symptoms (heartburn, regurgitation, dysphagia) with
5-point scale ranging from 0 (no symptoms) to 4 (disabling
ymptoms). They were also questioned about the use of acid-
educing medications (histamine 2–blocking agents and proton
ump inhibitors).
sophageal Manometry
sophageal manometry was performed after an overnight fast by
echniques previously described.12 Medications that might inter-
ere with esophageal motor function (ie, calcium-channel blocking
gents, nitrates, and metoclopramide) were discontinued at least 48
ours before the study. Position, pressure, length, and relaxation of
he lower esophageal sphincter (LES) were measured by the sta-
ion pull-through technique, with 0.5-cm increments between sta-
ions. Esophageal body function was recorded 3, 8, 13, and 18 cm
bove the upper border of the LES by giving 10 swallows of 5 mL
f water at 30-second intervals. Amplitude of peristaltic waves was
alculated independently for the distal (3 and 8 cm above the LES)
nd the proximal esophagus (13 and 18 cm above the LES).
sophageal length was measured from the upper esophageal
phincter (UES) to the distal end of the LES. Ineffective esopha-
eal motility was defined as distal esophageal amplitude less than
0 mm Hg or greater than 30% simultaneous waves in the distal
sophagus.13 Nonspecific esophageal motility disorder was de-
ned as the presence of abnormal esophageal peristalsis not meet-
ng the criteria for ineffective esophageal motility.
mbulatory pH Monitoring
roton pump inhibitors were withheld for 14 days and histamine-2
lockers were withheld for 3 days before the study in all patients.
he pH catheters were calibrated in a standard buffer solution at
H 1 and pH 7 before and after monitoring. A dual-channel pH
atheter with two antimony sensors located 15 cm apart was
laced transnasally, with the distal sensor 5 cm above the upper
order of the manometrically determined LES. Patients were
nstructed to consume an unrestricted diet, refrain from taking
ny acid-suppressing medications, and to keep a diary of symp-
oms during the pH testing. Data were incorporated into a com-
osite score (DeMeester score). A score greater than 14.7 was set
s abnormal on the basis of data obtained from 50 volunteers.14
he cohort was divided into two groups, GERD positive or neg-
tive, on the basis of the DeMeester score. Proximal reflux was
efined as greater than 1% total time that pH was less than 4 at the
roximal sensor.15 The data were analyzed with a commercial
oftware program (Gastrosoft; Medtronic Functional Diagnostic,
horeview, Minn).
tatistical Analysis
tatistical analysis was performed with STATA Statistical Soft-
are: Release 9.1 (Stata Corporation, College Station, Tex). Non-
arametric statistical analyses were performed. Differences be-
ween the two groups were analyzed with the 2 test for
roportions or the Mann–Whitney test for continuous variables.
ata are reported as number (percentage) from 2 analysis or as
edian (interquartile range) for nonparametric tests. Spearman
ank correlation was used to examine associations between con-
inuous or ordinal variables.
and Cardiovascular Surgery ● Volume 133, Number 4 1079
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1
TXThe study protocol was approved by the UCSF Committee for
uman Subjects Research.
esults
hirty patients completed their evaluation in the Swallow-
ng Center at UCSF. The patients with and without reflux
id not differ with respect to age, gender, body mass index,
r use of proton pump inhibitors before esophageal evalu-
tion (Table 1). Median estimated time between IPF diag-
osis and esophageal testing was 22 months (range 1-121
onths). A majority of subjects had been prescribed proton
ump inhibitors empirically or in conjunction with steroid
dministration for management of IPF. Fifteen (50%) pa-
ients were receiving steroid therapy at the time of referral
o the Swallowing Center. Abnormal reflux was seen in 80%
f patient not receiving steroids and in 53% of patients
eceiving steroids (P  .12) The groups were different with
espect to their pulmonary function testing. The group with
eflux had significantly better measures of forced expiratory
olume in 1 second (FEV1) and carbon monoxide diffusion
n the lung (DLCO). FEV1 and DLCO were correlated with
eMeester score (r  0.56 and 0.65, P  .0025 and .0002).
Five patients had endoscopic examination of the upper
sophagus. Hiatal hernias were identified in all 5. Abnormal
ucosal changes of the distal esophagus (irregular Z-line
nd/or erythema) were noted in 3 patients. All 5 subjects
ad abnormal DeMeester scores and 2 had abnormal prox-
mal reflux.
ymptomatic Assessment
wenty-seven subjects completed the symptom evaluation.
ixty-five percent of the subjects with abnormal esophageal
cid exposure reported one or more typical symptom, leav-
ng 35% with asymptomatic reflux. Conversely, among the
ubjects with normal esophageal acid exposure, 29% re-
ABLE 1. Demographics and pulmonary function tests
GERD  GERD  P value
emographics
No. of patients 20 10
Age 62 (56-64) 58 (54-61) .3
Male 17 (85%) 7 (70%) .33
BMI 27 (25-29) 27 (25-30) .51
Steroid use 12 (80%) 8 (53%) .12
PPI use before
study
14 (70%) 5 (50%) .28
ulmonary function
FEV1 (% predicted) 76 (65-94) 53 (52-58) .0004
DLCO (% predicted) 3962 (2157-6873) 2153 (1240-3257) .000627
MI, Body mass index; PPI, proton pump inhibitor; FEV1, forced expiratory
olume in 1 second; DLCO, diffusion of carbon monoxide in the lung.
ontinuous data are presented as the number and (percentage). Categor-
cal data are presented as the median and (interquartile range).orted typical reflux symptoms (Table 2). P
080 The Journal of Thoracic and Cardiovascular Surgery ● AprTo determine the utility of typical reflux symptoms as a
creening test for reflux, we compared the report of any one
r more typical symptoms with the esophageal pH findings.
atients who reported experiencing any heartburn, regurgi-
ation, and/or dysphagia were considered to have a positive
ymptom screening test. These data were then compared in
eparate 2  2 tables with the presence or absence of
bnormal distal and proximal acid exposure on 24-hour pH
onitoring (Table 3). The sensitivity and specificity for
istal reflux were 65% and 71%, respectively.
sophageal Manometry
atients with reflux had lower median LES pressures (12 vs
0 mm Hg; P  .01) and were more likely to have a
ypotensive LES (mean resting pressure 14 mm Hg)
65% vs 10%; P  .004; Table 4). Abnormal esophageal
eristalsis was more common among patients with reflux
50% vs 10%; P  .03; Table 5). In this group, 6 patients
ad nonspecific esophageal motility disorder (30%) and 4
atients had ineffective esophageal motility (20%). A single
atient with a normal distal and proximal esophageal acid
xposure had ineffective esophageal motility. Distal esoph-
geal wave duration was significantly shorter in those with
eflux, and there was a trend toward weaker distal esopha-
eal wave amplitudes, but this result was not statistically
ignificant. Median UES pressures were lower in those with
eflux than in those without (55 vs 84; P  .054).
wenty-four-hour pH Monitoring
bnormal distal esophageal acid exposure was found in
7% of the cohort, and abnormal proximal esophageal acid
xposure was found in 30% (Table 6). The data demonstrate
he substantial difference in the amount of reflux between
ABLE 2. Prevalence of reflux symptoms
GERD  GERD  P value
ny typical reflux symptom 65% 29% .10
eartburn 58% 29% .19
egurgitation 56% 14% .06
ysphagia 39% 14% .24
ABLE 3. Utility of symptomatic screening
Distal reflux Proximal reflux
ensitivity 65% 60%
pecificity 71% 39%
ositive predictive value 87% 21%
egative predictive value 42% 58%
omparison of the presence or absence of any typical reflux symptoms with
sophageal pH findings. See text. Distal reflux, DeMeester score 14.7.
roximal reflux, Proximal probe pH  4 for 1% of study time.
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TXhose with and without reflux. Mean esophageal acid clear-
nce time was longer among patients with reflux.
Proximal reflux was found in 9 (30%) patients. The
ajority of proximal reflux occurred in the upright position.
ne patient with normal distal acid exposure had abnormal
roximal esophageal acid exposure. This patient has normal
sophageal motility and a normal LES.
In addition to the 30 patients who were studied before
ransplantation, 6 additional patients with pathologic diag-
oses of IPF were studied after lung transplantation. All 6
atients were found to have elevated DeMeester scores
median 45, range 38-83) and 3 were found to have abnor-
al proximal acid exposure.
iscussion
hese data demonstrate that (1) reflux was prevalent and
requently extended into the proximal esophagus, (2) reflux
as associated with a hypotensive LES and abnormal
sophageal peristalsis, and (3) symptoms were not a reliable
eans of screening patients with IPF for reflux.
Symptoms have been shown not to be predictive of
espiratory symptoms attributed to GERD.16-18 This appears
o hold true among patients with IPF. Raghu and col-
eagues19 reported that typical symptoms were found in
7% of 65 patients with IPF. D’Ovidio and colleagues4
ABLE 4. Esophageal sphincter function
GERD  GERD  P value
ES pressure (mm Hg) 12 (9-18) 20 (16-24) .01
ypotensive LES (14mm Hg) 13 (65%) 1 (10%) .004
otal LES length (cm) 2.3 (1.9-4) 2.9 (2.3-3) .51
bdominal LES length (cm) 2 (1.1-2.3) 2.5 (2-3) .21
ES pressure (mm Hg) 55 (27-70) 84 (70-106) .054
ES, Lower esophageal sphincter; UES, upper esophageal sphincter. Con-
inuous data are presented as the median and (the interquartile range).
ategorical data are presented as the number and (percentage).
ABLE 5. Esophageal body function
GERD  GERD  P value
ormal peristalsis 10 (50%) 9 (90%) .03
SEMD 6 (30%) 0 .05
EM 4 (20%) 1 (10%) .49
EA (mm Hg) 78 (49-116) 109 (77-145) .10
ED (mm Hg) 3 (2.8-3.7) 4.3 (4-5) .01
EA (mm Hg) 45 (31-87) 61 (54-67) .34
ED (mm Hg) 2.3 (2-2.8) 3 (2.7-3.2) .12
sophageal length (cm) 27 (24-28) 26 (25-30) .70
SEMD, Nonspecific esophageal motility disorder; IEM, ineffective esoph-
geal motility; DEA, distal esophageal amplitude; DED, distal esophageal
uration; PEA, proximal esophageal amplitude, PED, proximal esophageal
uration. Continuous data are presented as the median and (the interquar-tile range). Categorical data are presented as the number and (percentage).
The Journal of Thoraciceported that 65% of 26 subjects with all-cause interstitial
ung disease referred for transplantation reported having
eflux symptoms. Neither of these studies reported the dif-
erent prevalence of symptoms among those with and with-
ut GERD. Our results demonstrate that symptoms cannot
e used to screen patients with moderate-to-severe IPF for
eflux. Objective esophageal testing is the only means cur-
ently available to screen for reflux in these patients.
Esophageal manometry demonstrated that reflux was as-
ociated with a hypotensive LES. Furthermore, 50% of
hose with reflux had abnormal esophageal peristalsis. In
hese patients, the two physiologic antireflux mechanisms
re impaired. The LES, the main barrier to reflux, is weak.
urthermore, the esophageal peristalsis is abnormal, so that
he refluxate remains in the esophagus for a longer period of
ime. This combination results in prolonged esophageal
xposure to reflux, which we suspect increases the likeli-
ood of aspiration.13
The prevalence of distal and proximal reflux was 67%
nd 30%, respectively. Raghu and colleagues19 found a
revalence of distal and proximal reflux of 76% and 63%
mong 46 patients with IPF. In that study, different proxi-
al esophageal testing procedures were used, with the prox-
mal probe at 15 cm above the LES or 2 cm above the UES.
he difference in measured prevalence of proximal reflux
ould be due to these methodological differences, chance, or
o referral bias. Proximal reflux is of particular importance
nasmuch as it has been associated with respiratory symp-
oms attributed to reflux and microaspiration.16,20 Among
ABLE 6. Esophageal pH findings
GERD  GERD  P value
istal probe
No. of reflux events 213 (129-280) 36 (27-57) .00005
Events 5 min 7 (4-10) 0 (0-1) .0001
Percent time pH  4 15 (9-21) 1.3 (0.6-2) .00005
DeMeester score 52 (38-85) 6 (4-8) .00005
roximal probe
No. of reflux events 21 (10-68) 4 (2-7) .012
Events 5 min 0 (0-1) 0 .06
Percent time pH  4 0.7 (0.1-2.4) 0 (0-0.2) .23
Percent time upright 1 (0.2-3) 0 (0-0.4) .01
Percent time supine 0.2 (0-1) 0 .025
Proximal reflux 8 (40%) 1 (10%) .09
learance time
Distal clearance 1 (0.8-1.2) 0.4 (0.3-0.7) 0.0014
Proximal clearance 0.3 (0.1-0.7) 0 (0-0.3) 0.06
ontinuous data are presented as the median and (the interquartile range).
ategorical data are presented as the number and (percentage). Distal
eflux is defined as DeMeester score 14.7. Proximal reflux is defined as
H  4 at the proximal probe for 1% of the study time. Mean clearance
imes are calculated by dividing the number of minutes pH 4 and dividing
y the number of reflux episodes. Units are minutes/episode.he 6 patients who were studied after transplantation, distal
and Cardiovascular Surgery ● Volume 133, Number 4 1081
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1
TXnd proximal reflux were seen in 100% and 50%, respectively.
ecause transplant has been shown to worsen reflux, these
atients were not included in the main analysis of this study.21
One patient had normal distal acid exposure but abnor-
al proximal acid exposure. Larger studies of patients with
ll-cause end-stage lung disease have also identified a sub-
et of patients with a similar reflux profile.4 In these pa-
ients, the quantity and frequency of distal reflux is physi-
logic, but most of that reflux extends into the proximal
sophagus. Single-channel distal esophageal pH monitor-
ng, therefore, will fail to identify this subgroup of patients
t increased risk for aspiration.
In our cohort, the patients with reflux had better pulmo-
ary function testing as measured by both FEV1 and DLCO.
his finding was contrary to our expectations. Raghu and
oworkers19 found no correlation between pulmonary func-
ion testing and amount of reflux. In that study, the 6
atients without reflux had lower mean values for forced
ital capacity and DLCO. Statistical analysis was limited by
he small group size. We are suspicious that the association
etween pulmonary function and reflux is a result of chance,
espite the strong statistical significance of the rank–sum
est. Alternatively, it may reflect an unidentified referral
ias. Increased negative intrathoracic inspiratory pressures
nd increased positive intra-abdominal pressures during
ough may contribute to reflux in patients with lung disease.
urprisingly, in this study, patients with less severe lung
isease had more reflux, suggesting that an increased thoraco-
bdominal pressure gradient is not the sole cause of reflux.
The principal limitations of this study are the small sample
ize and the potential for referral bias, inasmuch as the patients
ere seen in the context of referral for lung transplantation.
herefore, caution must be used when generalizing these find-
ngs to a broader population of patients with IPF.
Esophageal pH monitoring underestimates the amount
nd frequency of reflux. Unlike esophageal impedence test-
ng, pH monitoring does not detect nonacidic reflux or
easure the volume of the refluxate. Future studies should
se impedance technology.
In conclusion, this study shows that 30% of patients with
PF have gastroesophageal reflux that extends into the prox-
mal esophagus, putting them at high risk for recurrent
icroaspiration. Whether or not such reflux plays a causal
ole in IPF pathogenesis, progression, or acute exacerbation
s unknown. Ultimately, reflux is a surrogate marker of
spiration, and clarification of the role of reflux in IPF will
epend on demonstrating that reflux and/or aspiration are
isk factors for disease progression or death. These data
upport further efforts to study this association. Ultimately,
f such an association is causal, antireflux surgery may be
herapeutic for a subgroup of patients with IPF, blocking the
rogression of disease and perhaps avoiding the need for
ransplantation.
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TXiscussion
r Raphael Bueno (Boston, Mass). As mentioned, GERD has
een recently implicated in the etiology of rejection after lung
ransplantation. This finding has led many of us to explore the
ncidence of GERD in patients who are candidates for lung trans-
lantation, as was described in this presentation. This study shows
high incidence of documented GERD in patients with IPF
eferred for transplantation at one center. Two thirds of the patients
ere found to have reflux, and almost half of those had proximal
eflux. Also, many of these patients did not have symptoms. These
esults are certainly consistent with other reports and should lead
o the referral of potential recipients for lung transplantations for
outine evaluation for reflux.
The two questions I have, having read the manuscript, are as
ollows: Does this cohort include all of your patients with IPF
eferred for lung transplantation? A good control of the mechanism
f reflux would be evaluating the non-IPF patients. Have you
ooked at those patients and what have you found?
Dr Sweet. Thank you very much, Dr Bueno.
This represents almost all of our patients with IPF, but not
very single one. There were several patients who were not re-
erred for evaluation, probably about 4 or 5, and in another 2 or 3
atients the studies were not complete and so they are not included
n the analysis here.
In response to your other question, we have looked at 109 of
ur pretransplant patients thus far, inclusive, obviously, of all
auses of end-stage lung disease, and we have found similar
revalences of reflux, both proximal and distal, across the cohorts.
his includes patients with pulmonary hypertension and chronic
bstructive pulmonary disease, groups in which reflux has not
eally been considered to play a role in the etiology of the lung
isease. We have looked across the board, and it is really quite
revalent.
Dr Mark B. Orringer (Ann Arbor, Mich). There are a number
f issues that I would like to have you address just for the sake of
larity. This patient population is often using bronchodilators,
hich relax smooth muscle and therefore relax LES tone. They
lso use steroids, which increase gastric acid production. Have you
orrelated the drugs that the patients in your two groups were
aking to see whether there was a causal relationship between what
ou have determined to be reflux and nonreflux in the two groups?
Dr Sweet. We looked at the use of proton pump inhibitors. I
id not look specifically at the number of patients who were
eceiving steroids or bronchodilators at the time that they were
eferred for evaluation at the Swallow Center. Seventy percent of
he patients with reflux had been started on proton pump inhibitors
mpirically before referral to the Swallowing Center and 50% of
he patients without reflux had also been started empirically, and
ost of those were in conjunction with treatment with steroids, but
do not know exactly how many had been receiving steroids at the
ime of referral.
Dr Orringer. So one issue is whether or not the reflux that we
re treating is iatrogenic and not inherent in these patients.
The second issue has to do with interpreting the results of
4-hour pH monitoring in these patients. When patients with a
hronic cough or other similar respiratory symptoms are sent to us
or an antireflux operation, having several hundred episodes of
reflux” recorded on 24-hour distal esophageal pH monitoring, are w
The Journal of Thoracice to conclude that they are really in desperate straits and need the
urgery? I always look at these data with a somewhat jaundiced
ye, because so many of these patients are chronic air swallowers
nd are belching all the time. When you see what is recorded as
reflux episodes,” you may actually be looking at documentation
f physiologic reflux with belching and not necessarily pathologic
eflux. I would like to ask Toni Lerut to comment on this. I do not
hink that pathologic reflux typically presents with 100 to 200
reflux episodes” on 24-hour pH monitoring.
Did you differentiate upright reflux from supine reflux? Many
upright refluxers” in my experience tend to be more physiologic
efluxers with frequent belching. At issue is how we definitively
rove that aspiration of gastric contents into the tracheobronchial
ree is occurring. We heard some time ago about the Bilitech
atheter (Medtronic, Inc, Minneapolis, Minn) being used to detect
ile reflux. I have not heard much more about this technology
ecently. What really is needed is a probe that can be passed down
he bronchoscope to detect bile in the airways, documenting aspi-
ation of gastric contents. I wonder whether you could comment on
his as well.
Dr Sweet. To answer your first question, we did look at upright
nd supine reflux, and the predominance of reflux was in the
pright position. Also, as I tried to point out during the talk,
obody really knows which parameter is the most predictive of
isk for microaspiration. We do not know objectively which risk
actor is the most dangerous, but a statistically significant higher
ercentage of the patients have these episodes lasting longer than
minutes, and many of them have proximal episodes lasting
onger than 5 minutes, that is, 4 or 5 episodes lasting longer than
minutes during the 24-hour study period. Someone who has a
otal of half an hour throughout the course of the day of proximal
sophageal acid exposure is at very high risk for microaspiration.
owever, I understand your point that there is not necessarily a
ingle parameter that we can use to determine who is microaspi-
ating. That gets to your second point, which is that really we are
sing reflux as a surrogate marker of microaspiration. That is what
ur group is actually working on. We have started recruiting
atients already, looking at markers of microaspiration, specifi-
ally pepsin, in both bronchoalveolar lavage samples, and we are
lso trying to look for a noninvasive way to screen for that. That
ould provide a much more powerful diagnostic measure to look
or what we are concerned about, which is the microaspiration
vent. Therefore, I concur and we are starting to do that now. I
ould certainly appreciate hearing the thoughts of anybody else
ho is working on that.
Dr Antoon E. M. R. Lerut (Leuven, Belgium). In follow-up of
ark Orringer’s remarks, I have a comment and not a question.
I think impedance is probably going to give us far better insight
nto the problems of belching, nonacidic reflux, or perhaps acid
oming up into the esophagus with air belching. Clearly, imped-
nce will certainly become a helpful tool to investigate problems
f supraesophageal reflux.
Dr Tomasz Grodzki (Szczecin, Poland). I have two questions.
irst, you mentioned that the patients were in end-stage IPF on the
asis of radiologic or biopsy confirmation. While I noticed in one
f the slides that the FEV1 was 76% and DLCO more than 60%,
ere they really suitable candidates for transplantation? Second,
and Cardiovascular Surgery ● Volume 133, Number 4 1083
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TXid you perform any manometry or pH measurements postopera-
ively?
Dr Sweet. To answer your first question, you are correct. I
hould not have used the word “end-stage.” The patients were a
ix of subjects with moderate to end-stage IPF. That is certainly
ne of the limitations of our study; we have kind of a cohort of
atients who were referred for evaluation for transplantation. A
atural history paper, written by Dr Martinez,22 came out of the
nterMune study of interferon. This paper showed that nearly 20%
f the patients died within 1½ years of follow-up, and more than
alf of those died of abrupt clinical deterioration without demon-
trable progression of their IPF in the time period. Because of that,
he pulmonologists in our group are trying to refer the patients for
ransplantation sooner than they had in the past. That is the reason
e have a heterogeneous group of patients with IPF with respect to
he degree of their lung disease. I hope that answers your question. It
s one of the problems. The only patients we have been able to get into
he Swallowing Center are the patients who come through the trans-
lant clinic. The other pulmonologists have not yet gotten on board
ith this, and this is one of the reasons we did the study—to try to get
broader group of patients with IPF referred.
Concerning the second question, looking at reflux and manom-
try in the posttransplant setting, we have studied 8 to 10 patients,
nd I actually do not know what lung disease subgroups they all
re. There are at least 6 who have IPF. All 6 with IPF who were
tudied after transplant had abnormal DeMeester scores. I think the
edian was in the 40 to 50 range, and half of them had abnormal
roximal reflux. So the numbers were higher. Again, there is a
aper from Duke23 comparing the pretransplant and posttransplant
sophageal studies, and these investigators found an increase in the
verall prevalence of reflux after transplantation. Our small
mount of data corroborates that.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). We have
een studying this in detail, as you know, because of the associ-
tion between reflux and bronchiolitis obliterans after transplanta-
ion. As Dr Orringer pointed out, it is likely a combination of
ffects of the drugs these patients are receiving, the change in the
natomy of their chest as the lungs either contract or expand
epending on their lung disease, possible injury to the vagus nerve
t the time of transplant, and then the posttransplant medications,
uch as cyclosporine. We have started to try to tease out the
ontributions of these various factors.
With respect to the functional issues, we have documented a
igh prevalence, as you know from our published work, of reflux
n the pretransplant patients, which was not greatly increased after
ransplantation. The surgeons were thankful to see that. But one of
he things that needs further study is the supine versus upright
ssue and, second, confirming it with measurement of bile acids in
ronchoalveolar lavage. There is an assay, which is quite accurate,
hat correlates highly with the development of bronchiolitis oblit-
rans. I think that it is real in these patients. What is also interest-
ng is that a lot of patients did not have acid reflux, but possibly
ad nonacid reflux or bile reflux. The impedance catheter will
ore clearly detect these patients. On the other hand, we have also
oted that some patients actually experienced an improvement in
he degree of reflux after transplantation. We speculated that we
ad changed where the LES complex sat in the chest relative to the
bdomen with the realigning of the anatomy of the chest with a t
084 The Journal of Thoracic and Cardiovascular Surgery ● Aprransplant. There is indeed a lot of very interesting work to be done
o figure all of this out.
Dr Joshua R. Sonett (New York, NY). I have one question.
ou are talking about IPF in general. Did you look at nonspecific
nterstitial pneumonia versus unusual interstitial pneumonia, be-
ause at least 40% to 60% of our patients with IPF have sclero-
erma and other mixed connective tissue diseases and a really
nfunctional esophagus in a number of ways.
Dr Sweet. We actually excluded all patients with nonspecific
nterstitial pneumonia. As I said, we had tissue diagnoses in 25 of
he 30 patients, and in the other 5 the diagnosis was based on the
linical criteria from the ATS/ERS consensus statement. As I think
ou are aware, that is not 100% sensitive and specific, but we did
xclude the patients with nonspecific interstitial pneumonia and
ried to get as pure an IPF cohort as we could for this study.
Dr Sonett. Unusual interstitial pneumonia is probably a better
ay of expressing that.
Dr Sweet. Yes, I should say unusual interstitial pneumonia.
hank you.
Dr Keshavjee, your paper on bronchiolitis obliterans syndrome
nd bile acids has been for me the most stimulating paper on this
opic. Concerning your comment, from the general reflux data, we
nderstand about 60% of patients have duodenal gastroesophageal
eflux, so that is where we are going to see the bile. I am optimistic
hat looking at pepsin, which is a more specific marker for gastro-
sophageal reflux, will, I hope, identify all those patients who are
icroaspirating. After we have had a chance to collect some data, it
ill be interesting to look at which patients have duodenal gastro-
sophageal reflux and which have just gastroesophageal reflux.
Dr William A. Baumgartner (Baltimore, Md). I am intrigued
y this. This is a little bit different take on Dr Orringer’s question.
re there any data that suggest that this causes IPF?
Dr Sweet. I am aware of no data correlating the presence of
eflux with outcome and IPF or in terms of seeing patients who
ave reflux who later have IPF develop. I think that is a very
ifficult problem to address. Obviously, reflux is highly prevalent.
hen how do you monitor those patients long enough to see
hether their risk of developing IPF is different from that of the
eneral population? I hope that answers your question.
Dr Baumgartner. Yes. I just wonder whether it is the chicken
nd the egg here, whether anybody really knows. We know it has
een shown that perhaps IPF contributes to bronchiolitis obliterans
yndrome, but is it the other way around possibly?
Dr Sweet. I think the only other data that are available are
necdotal. I have spoken briefly with Dr Bueno about this, and I do
ot want to speak on his behalf. However, I know that in our center
e have 1 or 2 patients who underwent antireflux surgery with a
iagnosis of IPF and were able then to come off the transplant list.
understand that Dr Bueno has had a similar experience at his
nstitution. I think he said that he had 3 patients. Thus there is
necdotal evidence that patients with IPF undergoing antireflux
urgery had a significant clinical benefit. However, it is really hard
o generalize from anecdotal data. When we can look both in the
re-antireflux and post-antireflux surgery setting at markers of
icroaspiration and see that we have stopped that and then those
atients who no longer have markers of microaspiration are doing
etter, that would be the best data that we will be able to generate
o support the application of antireflux surgery in these patients.
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